PortalPublikationen[Warm autoimmune hemolytic anemias and Evans syndrome in adu...

[Warm autoimmune hemolytic anemias and Evans syndrome in adults]

Standard

[Warm autoimmune hemolytic anemias and Evans syndrome in adults]. / Michel, Melanie.

in: REV MED INTERNE, Jahrgang 29, Nr. 2, 2, 2008, S. 105-114.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Michel, M 2008, '[Warm autoimmune hemolytic anemias and Evans syndrome in adults]', REV MED INTERNE, Jg. 29, Nr. 2, 2, S. 105-114. <http://www.ncbi.nlm.nih.gov/pubmed/17980462?dopt=Citation>

APA

Michel, M. (2008). [Warm autoimmune hemolytic anemias and Evans syndrome in adults]. REV MED INTERNE, 29(2), 105-114. [2]. http://www.ncbi.nlm.nih.gov/pubmed/17980462?dopt=Citation

Vancouver

Michel M. [Warm autoimmune hemolytic anemias and Evans syndrome in adults]. REV MED INTERNE. 2008;29(2):105-114. 2.

Bibtex

@article{925836caa7bc4b76b52c6ea3574fecc0,
title = "[Warm autoimmune hemolytic anemias and Evans syndrome in adults]",
abstract = "PURPOSE: The outcome of autoimmune hemolytic anemia (AIHA) and Evans syndrome (ES) in adults is not well-known and their management is mainly based on empirical data. CURRENT KNOWLEDGE AND KEY POINTS: The main characteristics of both AIHA and ES are reviewed in this article, based on the data available in the literature and on our experience. Although controlled studies and evidence-based data are lacking, some recommendations regarding the minimal workup useful to search for an underlying disease can be made as well as proposals for a better therapeutic strategy of both disorders. FUTURE PROSPECTS AND PROJECTS: A better knowledge of the mechanisms triggering AIHA and ES as well as therapeutic trials are needed in order to better stratify treatment taking into account the promising efficacy of rituximab.",
author = "Melanie Michel",
year = "2008",
language = "Deutsch",
volume = "29",
pages = "105--114",
journal = "REV MED INTERNE",
issn = "0248-8663",
publisher = "Elsevier Masson",
number = "2",

}

RIS

TY - JOUR

T1 - [Warm autoimmune hemolytic anemias and Evans syndrome in adults]

AU - Michel, Melanie

PY - 2008

Y1 - 2008

N2 - PURPOSE: The outcome of autoimmune hemolytic anemia (AIHA) and Evans syndrome (ES) in adults is not well-known and their management is mainly based on empirical data. CURRENT KNOWLEDGE AND KEY POINTS: The main characteristics of both AIHA and ES are reviewed in this article, based on the data available in the literature and on our experience. Although controlled studies and evidence-based data are lacking, some recommendations regarding the minimal workup useful to search for an underlying disease can be made as well as proposals for a better therapeutic strategy of both disorders. FUTURE PROSPECTS AND PROJECTS: A better knowledge of the mechanisms triggering AIHA and ES as well as therapeutic trials are needed in order to better stratify treatment taking into account the promising efficacy of rituximab.

AB - PURPOSE: The outcome of autoimmune hemolytic anemia (AIHA) and Evans syndrome (ES) in adults is not well-known and their management is mainly based on empirical data. CURRENT KNOWLEDGE AND KEY POINTS: The main characteristics of both AIHA and ES are reviewed in this article, based on the data available in the literature and on our experience. Although controlled studies and evidence-based data are lacking, some recommendations regarding the minimal workup useful to search for an underlying disease can be made as well as proposals for a better therapeutic strategy of both disorders. FUTURE PROSPECTS AND PROJECTS: A better knowledge of the mechanisms triggering AIHA and ES as well as therapeutic trials are needed in order to better stratify treatment taking into account the promising efficacy of rituximab.

M3 - SCORING: Zeitschriftenaufsatz

VL - 29

SP - 105

EP - 114

JO - REV MED INTERNE

JF - REV MED INTERNE

SN - 0248-8663

IS - 2

M1 - 2

ER -